Zacks Investment Research Downgrades UCB (OTCMKTS:UCBJF) to Strong Sell

UCB (OTCMKTS:UCBJFGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research report issued on Friday, reports.

According to Zacks, “UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson’s disease. It also provides therapy in the areas of oncology, immunology, inflammation, allergy and respiratory diseases. UCB delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. “

Other analysts also recently issued research reports about the stock. Cowen started coverage on shares of UCB in a report on Friday, January 21st. They issued an “outperform” rating for the company. UBS Group upgraded shares of UCB from a “sell” rating to a “neutral” rating and set a $105.00 target price for the company in a report on Wednesday, March 23rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $95.00 target price on shares of UCB in a report on Friday, May 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $114.88.

Shares of UCBJF stock opened at $92.18 on Friday. The firm has a 50-day moving average of $114.55 and a 200-day moving average of $111.11. The company has a current ratio of 1.31, a quick ratio of 1.00 and a debt-to-equity ratio of 0.25. UCB has a one year low of $90.93 and a one year high of $122.90.

UCB Company Profile (Get Rating)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Featured Articles

Get a free copy of the Zacks research report on UCB (UCBJF)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for UCB (OTCMKTS:UCBJF)

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with's FREE daily email newsletter.